Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcadia BiosciencesRKDA -18.59%43 Net-Net Working Capital is $0.98 as of Mar. 2026. GuruFocus rates RKDA with a GF Score™ of 43/100 and a GF Value™ of $2.84 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 661 Consumer Packaged Goods companies, Arcadia Biosciences ranks better than 97.13% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Arcadia Biosciences's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.98.
The industry rank for Arcadia Biosciences's Net-Net Working Capital or its related term are showing as below:
RKDA's Price-to-Net-Net-Working-Capital is ranked better than 97.13% of 661
companies
in the Consumer Packaged Goods industry
Industry Median: 6.82
vs RKDA: 0.57
Arcadia Biosciences (NAS:RKDA) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Arcadia Biosciences Net-Net Working Capital Related Terms
Arcadia Biosciences Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RKDA vs ORISF, ARRT, CIMG: Net-Net Working Capital Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences Price-to-Net-Net-Working-Capital vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.98 mean?
Arcadia Biosciences (RKDA) has a Net-Net Working Capital of $0.98 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Arcadia Biosciences According to the industry distribution chart, Arcadia Biosciences ranks #19 out of 661 companies in the Consumer Packaged Goods industry, placing it in the top 2.9%.
Is Arcadia Biosciences' Net-Net Working Capital too high?
Arcadia Biosciences' current Net-Net Working Capital is $0.98. The Consumer Packaged Goods industry median Net-Net Working Capital is 6.82. Arcadia Biosciences' value of $0.98 is 85.6% below this industry median. Based on the distribution chart, Arcadia Biosciences ranks #19 out of 661 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Arcadia Biosciences has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' Net-Net Working Capital compare to ORISF and ARRT?
According to the Consumer Packaged Goods industry distribution chart, Arcadia Biosciences ranks #19 out of 661 companies for Net-Net Working Capital. This places Arcadia Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.82. Arcadia Biosciences' value of $0.98 is 85.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Consumer Packaged Goods company?
The median Net-Net Working Capital among Consumer Packaged Goods companies is 6.82, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcadia Biosciences's current Net-Net Working Capital of $0.98 is 85.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Arcadia Biosciences For the Consumer Packaged Goods industry, the median Net-Net Working Capital is 6.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcadia Biosciences's current Net-Net Working Capital is $0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcadia Biosciences (RKDA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.84, compared to a current price of $0.56 — trading 80.3% below its estimated fair value. The current Net-Net Working Capital is $0.98 and 85.6% below the Consumer Packaged Goods industry median of 6.82. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Arcadia Biosciences (RKDA), the current Net-Net Working Capital is $0.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (RKDA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of $0.56 is trading 80.3% below its estimated GF Value™ of $2.84.
GuruFocus considers Arcadia Biosciences to be Possible Value Trap.
Key valuation signals for RKDA:
Net-Net Working Capital: $0.98
GF Value™: $2.84 vs. price of $0.56 (80.3% below fair value)
Industry Position: 85.6% below the Consumer Packaged Goods median (#19 of 661)
No single metric tells the full story. See the RKDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for RKDA
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RKDA has been successfully added to your 
